High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)
- no estimate extracted1 study · 46 participantsVery low
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
It is very uncertain whether 150,000 IU of vitamin D changes ulcer healing (absolute change in individual parameters of ulcer… compared with 300,000 IU of vitamin D (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Prostate cancer: OR 1.04 (95% CI 0.98 to 1.09), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Type 2 diabetes: OR 0.63 (95% CI 0.56 to 0.69), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Sporadic colorectal adenoma recurrence: OR 0.87 (95% CI 0.57 to 1.33), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Ischaemic heart disease: HR 0.72 (95% CI 0.65 to 0.81), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Breast cancer (Premenopausal): RR 1.01 (95% CI 0.97 to 1.06), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality, Patients with chronic kidney disease: RR 0.86 (95% CI 0.81 to 0.92), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Metabolic syndrome (prevalent): OR 0.49 (95% CI 0.38 to 0.64), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Cognition: OR 0.42 (95% CI 0.34 to 0.53), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Pancreatic cancer: OR 2.13 (95% CI 1.02 to 4.47), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Hip fracture (Population-based controls): log ratio of geometric mean -0.51 (95% CI -0.64 to -0.38), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Non-Hodgkin's lymphoma (Females): OR 0.81 (95% CI 0.39 to 1.70), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Hypertension: RR 0.70 (95% CI 0.58 to 0.86), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Aggressive prostate cancer: OR 0.98 (95% CI 0.84 to 1.15), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.